Overview

Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma

Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to assess the efficacy of SCIOS-469 as monotherapy in relapsed, refractory patients with multiple myeloma (MM), based on response rates.
Phase:
Phase 2
Details
Lead Sponsor:
Scios, Inc.
Treatments:
Bortezomib